<DOC>
	<DOC>NCT02676310</DOC>
	<brief_summary>This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).</brief_summary>
	<brief_title>Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year History of Paget's disease, osteoporosis, or bone malignancy History of bone fracture within the previous 12 months, except for metatarsal, metacarpal, or skull fractures Patient is currently undergoing radiation therapy or anticipates undergoing radiation therapy at any time during the study Drug or alcohol abuse within 12 months HIV positive Received hair transplants or had scalp reductions Use of hair weaves, hair extensions or wigs within 3 months Application of topical medications, minoxidil or nonsteroidal antiinflammatory drugs (NSAIDs) to scalp within 4 weeks</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>